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The Rise and Fall of the MMR Litigation: A 
Comparative Perspective 
The Rise and Fall of the MMR Litigation 
I. INTRODUCTION 
Autism is the term used to describe ‘a complex and severe set of developmental 
disorders characterised by sustained impairments in social interaction, impairments in 
verbal and nonverbal communication, and stereotypically restricted or repetitive 
patterns of behaviours and interests’.1 Over the last 15 years, stories surrounding the 
challenging condition of autism have never been far from the headlines. Many parents 
who have autistic children continue to search for a possible cause. When, in 1998, 
Andrew Wakefield and his colleagues hypothesised that there could be an association 
between the Measles, Mumps, Rubella (MMR) vaccine and autism, several though 
not all parents of autistic children became partially or totally convinced that this was 
the answer.
2
 As a consequence, many parents in the UK took to seeking legal advice 
as to whether they could proceed in a legal action against the manufacturers of the 
vaccine. In the US, these proceedings were brought against the Secretary for Health 
and Human services under the National Childhood Vaccine Compensation Program.  
This chapter seeks to assess the significance of the rise and fall of this 
litigation in the US and UK. The importance of the 1998 Wakefield study to the 
fuelling of such litigation is explained, as well as the reasons for its collapse pre-trial 
in the UK. It then examines the value of the relevant scientific evidence exposed in 
six test cases of the Omnibus Autism Proceeding (OAP) under the National 
Childhood Vaccine Injury Act of 1986 (NVIA), decided in February 2009 and March 
2010. These cases essentially explored two causation theories, viz that MMR vaccines 
and thimerosal-containing vaccines could combine to cause autism, and that 
thimerosal vaccines alone can cause autism. The legal implications of these complex 
and lengthy judgments are explored. The position in the United States is contrasted 
with the much more liberal approach to causation established in France by the Cour 
de Cassation for medicinal product liability cases in the context of injury allegedly 
caused by the Hepatitis B vaccine through the use of presumptions of causation.  
Finally, a discussion of the outcome of the General Medical Council Hearing 
on Dr Wakefield and his two co-authors of the 1998 study is provided. The paper 
                                                 
* I am grateful to the General Medical Council for permission to use the Transcripts of the hearings of 
the Fitness to Practise Panel (Misconduct) in the case of Wakefield, Walker-Smith and Murch, 16 July 
2007 to 24 May 2010 in the writing of this chapter. 
1
 Institute of Medicine, Immunization Safety Review: Vaccines and Autism (Washington DC, The 
National Academies Press, 2004), Executive Summary, p 3. 
2
 See especially, D Goldberg, ‘MMR, autism, and Adam’ (2000) 320 British Medical Journal 389. (In 
this Personal View for the British Medical Journal, Professor David Goldberg, a consultant clinical 
epidemiologist and Honorary Professor of Public Health at the University of Glasgow, wrote about his 
then 10-year-old son who is severely autistic, commenting that, by virtue of his NHS and public health 
affiliations, he was ‘tarred with the establishment brush’ by some parents of other autistic children for 
failing to join the ‘Wakefield bandwagon’). 
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concludes with some lessons to be learned from this litigation, both in the UK and in 
France in the light of its liberal approach.  
II. BACKGROUND: THE VACCINES AND AUTISM 
CONTROVERSY  
The Vaccines and Autism Controversy 
The hypothesis that the receipt of the MMR vaccine was linked to the development of 
autism spectrum disorders and gastrointestinal problems in children principally 
emerged from the notorious (now retracted) paper by Andrew Wakefield, then of the 
Royal Free Hospital in London, John Walker-Smith and 11 other colleagues from the 
same institution.
3
 This paper was published in The Lancet on 28 February 1998, and it 
reported on 12 children with chronic enterocolitis and regressive developmental 
disorder. Until its retraction on 6 February 2010,
4
 it was this publication that provided 
the basis for litigation both in the UK and US and generated ‘a decade long public 
health scare,
5
 which has led to hundreds of thousands of children in the UK being 
unprotected.
6
 The paper noted that the ‘onset of behavioural symptoms was associated 
by the parents with measles, mumps, and rubella vaccination in eight of the 12 
children’, and that in eight children, ‘the average interval from exposure to first 
behavioural symptoms was 6.3 days (range 1–14)’.7 Over the ensuing decade, the 
epidemiological evidence has consistently shown no causal link between MMR 
vaccine and autism and inflammatory bowel disease.
8
  
III. UK MMR LITIGATION 
A. Legal Aid Funding and Establishment of Group Litigation 
By far the majority of claims against the manufacturers of the MMR vaccine were 
initially funded by the Legal Aid Board in England and Wales (which became the 
Legal Services Commission).
9
 This body was responsible for providing legal aid for 
                                                 
3
 AJ Wakefield, et al, ‘Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive 
developmental disorder in children’ [retracted] (1998) 351 Lancet 637–41); The Editors of The Lancet, 
‘Retraction-Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental 
disorder in children’ (2010) 375 Lancet 445.  
4
 The Editors of The Lancet, ‘Retraction-Illeal-lymphoid-nodular hyperplasia, non-specific colitis, and 
pervasive developmental disorder in children’ (2010) 375 Lancet 445.  
5
 B Deer, ‘How the Case Against the MMR Vaccine Was Fixed’ (2011) 342 British Medical Journal 
77. 
6
 F Godlee, J Smith and H Marcovitch, Editorial, ‘Wakefield’s article linking MMR vaccine and autism 
was fraudulent’ (2011) 342 British Medical Journal 64, 65. 
7
 AJ Wakefield, et al, ‘Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive 
developmental disorder in children’ [retracted] (1998) 351 Lancet 637, 638. 
8
 See below, n 53. 
9
 Access to Justice Act 1999, s 1. Repealed by Legal Aid, Sentencing and Punishment of Offenders Act 
2012, Sch 5(1) para 51(a) (1 April 2013 subject to saving and transitional provisions as specified in SI 
2013/534, regs 6–13). The Legal Services Commission was abolished by the Legal Aid, Sentencing 
and Punishment of Offenders Act 2012, s 38. An Executive Agency within the Ministry of Justice (the 
Legal Aid Agency) has been created within the Ministry of Justice to administer legal aid. 
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Multi-Party Actions, providing that the individuals satisfied a financial means test and 
that the case met a legal merits test, which required cases to have a reasonable 
prospect of success, and for the costs of the action to be reasonable, compared to the 
potential damages.
10
 Consequent upon representations in the form of a proposed 
protocol and costing proposals by Richard Barr (a solicitor in England, who had 
public funding in relation to the pursuit of litigation against manufacturers of the 
MMR vaccine, viz GlaxoSmithKline, Aventis Pasteur and Merck) the Legal Aid 
Board authorised funding of £50,000 in two instalments of £25,000, in late 1996 and 
1999 respectively, for Wakefield to investigate a potential link between MMR and 
autism in respect of 10 named children.
11
 This money was paid into a numbered 
hospital charity account which was held by the Special Trustees of the Royal Free 
Hampstead NHS Trust, and then paid out for research by Wakefield on the MMR 
vaccine in the medical school.
12
 At least four of the eventual 12 children included in 
the Lancet Study were involved in the investigations which were covered by Legal 
Aid funding.   
As a result of a confidential report to the Legal Aid Board in January 1999,
13
 
one month later the Legal Aid Board awarded £800,000 to Unigenetics, a company 
incorporated with Wakefield and a Dublin pathologist, John O’Leary as directors, to 
perform polymerase chain reaction tests on the bowel tissue and blood samples of 
children in order to provide evidence of the alleged vaccine-derived measles virus.
14
 
A Practice Direction of 8 July 1999, promulgated by the then Lord Chief Justice of 
England and Wales, resulted in all claims for damage alleged to have arisen out of the 
inoculation with the MMR/MR vaccines being given the status of, and being dealt 
with under the umbrella of, Group Litigation.
15
  
B. Withdrawal of Funding and Dissolution of Group Litigation 
However, in December 1999, in the light of increasing concerns about a potentially 
serious conflict of interest between Wakefield’s academic employment by University 
                                                 
10
 The Legal Services Commission (LSC) Funding Code set out the criteria according to which cases 
could be funded, in accordance with the Access to Justice Act 1999, s 8 (repealed by Legal Aid, 
Sentencing and Punishment of Offenders Act 2012, Sch 5(1) para 51(a)). The criteria were laid down in 
Part 1 of the Code. The criteria for Multi-Party Actions (MPAs) are described in the Legal Services 
Commission Manual, vol 3, Part C, ch 15. See also the Legal Services Commission Manual, vol 3, Part 
C, ch 4, Merits, Costs and Damages. From 1 April 2013, civil legal services provided in relation to 
personal injury or death are exempted from legal aid: Legal Aid, Sentencing and Punishment of 
Offenders Act 2012, Sch 1, Part 2. Personal injury claims against pharmaceutical companies will no 
longer be eligible for legal aid.  
11
 General Medical Council, Fitness to Practise Panel (Misconduct), Day 11, 30 July 2007, Transcript, 
11-4C–11-17H, 11-26B–E. For discussion of the history of the anti-MMR campaign, including Mr 
Barr’s involvement, see M Fitzpatrick, MMR and Autism: What Parents Need to Know (London and 
New York, Routledge, 2004) 101–17. 
12
 General Medical Council, Fitness to Practise Panel Hearing, 28 January 2010, p 6. It subsequently 
transpired that Wakefield had failed to inform either his colleagues at the Royal Free, or the editor of 
The Lancet, about his involvement in the MMR litigation and his personal interest in establishing the 
autism link: see below, V.A.  
13
 AJ Wakefield, ‘Developmental disorders in children and measles, mumps, rubella (MMR) vaccine, 
Interim Report to the Legal Aid Board’, January 1999, cited in B Deer, ‘How the Vaccine Crisis was 
Meant to Make Money (2011) 342 British Medical Journal 136, 142, fn 24. 
14
 B Deer, ‘How the Vaccine Crisis was Meant to Make Money’ (2011) 342 British Medical Journal 
136, 140.  
15
 Practice Direction: MMR/MR Vaccine Litigation, 8 July 1999. 
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College London (UCL),
16
 and his involvement in a company to develop products 
based on his MMR claims, the provost of UCL demanded that Wakefield confirm or 
refute the possible causal relationships between MMR and autism/autistic 
enterocolitis/inflammatory bowel disease.
17
 The study never transpired, as the original 
study had been fraudulent and it would have been impossible to replicate it with 
greater numbers. Wakefield then left UCL.
18
 Over the next few years a series of 
epidemiological studies were published which repeatedly found no evidence of a 
causal link between the MMR vaccine and autism or bowel disorder. Accordingly, 
following counsel for the claimants’ submission of a report to the Legal Services 
Commission that they were unable to establish a case that MMR causes autism or 
bowel disease, on 29 September 2003 the Legal Services Commission decided to 
cease all funding for cases related to autism and bowel disease on the grounds that the 
litigation had no reasonable prospect of success. The decision was supported on 30 
September 2003 by the Funding Review Committee (FRC), an independent appeal 
body chaired by a Queen’s Counsel and three expert solicitors. The High Court 
rejected an application for a judicial review of the decision on 27 February 2004.
19
 37 
individual appeals were then heard by the FRC, which upheld the LSC’s decision to 
cease all funding for cases related to autism and bowel disease on 15 October 2004.
20
 
With only two claimants continuing with claims (those two having had their public 
funding restored, the rest having had their funding withdrawn by the Legal Services 
Commission), and there being no realistic prospect of any new claims being 
progressed in the light of the unavailability of public funding, the status of the 
litigation as group litigation was dissolved in June 2007.
21
 It was stressed, however, 
that the claims were not being allowed to proceed not because the court believed that 
the claims had no merit (which had never been addressed by the court), but because it 
was not practicable for the claims to go ahead without public funding.
22
 
IV. THE US OMNIBUS AUTISM PROCEEDING TEST 
CASES 
The US Omnibus Autism Proceeding 
A. The Omnibus Autism Proceeding (OAP) 
Just as the UK MMR litigation was grinding to a halt in 2007, the United States were 
about to commence three test cases in the Omnibus Autism Proceeding (OAP) under 
the National Childhood Vaccine Injury Act of 1986 (NVIA). The OAP is a 
                                                 
16
 The Royal Free and University College Medical Schools had now merged. 
17
 B Deer, ‘How the Vaccine Crisis was Meant to Make Money (2011) 342 British Medical Journal 
136, 142.  
18
 ibid.  
19
 ‘Parents refused aid to fight MMR’, 27 February 2004, available at: 
news.bbc.co.uk/1/hi/health/3494360.stm. 
20
 Press Release, MMR Appeals, 15 October 2004, available at: 
www.legalservices.gov.uk/press/press_release31.asp; C Dyer, ‘Parents claiming a link between MMR 
vaccine and autism lose final appeal for legal aid’ (2004) 329 British Medical Journal 939. 
21
 See Re MMR and MR Vaccine Litigation; Sayers and others v Smithkline Beecham plc and others 
[2007] EWHC 1335, QB, [2007] All ER (D) 67 (Jun), [35], [37].  
22
 ibid [37], Keith J.  
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coordinated proceeding, established in July 2002 and devised as a means by which 
5,000 cases filed with the National Childhood Vaccine Injury Compensation Program 
– in which it has been alleged that autism or a similar disorder was caused by one or 
more vaccines – could be handled by the program in a timely and effective manner.23 
The Office of Special Masters of the US Court of Federal Claims did this by dividing 
the claims into several theories of causation, and allocating three test cases for each 
theory. Shortly before the first test case, Cedillo, was due to begin, the US Secretary 
of Health and Human Services was granted permission to obtain from the records of 
the English High Court, copies of expert witness reports filed by the defendants in the 
UK MMR/MR Vaccine Litigation, so as to use these documents in the Omnibus 
Autism Proceedings in the US.
24
   
While the court cases in the UK were brought against the three manufacturers 
of the MMR vaccine, GlaxoSmithKline, Aventis Pasteur and Merck, cases under the 
National Childhood Vaccine Injury Compensation Program are brought against the 
Secretary for Health and Human Services. Unlike in the UK, where proceedings never 
reached the trial stage, in the US there has been an exhaustive analysis of the 
scientific and legal evidence by the Special Masters of the Court of Federal Claims. In 
the context of the US MMR Litigation, the assessment of the value of the scientific 
evidence came to prominence in the first three test cases of the OAP under the NVIA, 
which were decided in February 2009, as well as a further three test cases in March 
2010. A group of counsel selected from attorneys representing petitioners in the 
autism cases, known as the Petitioners’ Steering Committee (PSC) – which was 
established in 2002 to obtain and present evidence on the general issue of whether 
certain vaccines could cause autism and, if so, in what circumstances
25
 – presented 
two different theories of ‘general causation’ in the OAP, designating three ‘test cases’ 
for each of the two theories. The long-awaited test cases in these proceedings are of 
considerable importance, since they have irrefutably rejected the petitioners’ first and 
second general causation theories. The Special Masters in these proceedings, having 
considered all the available scientific evidence, concluded in the first three test cases 
that there was no merit in the petitioners’ first general causation theory that MMR 
vaccines and thimerosal-containing vaccines could combine to cause autism, and 
concluded in the second three test cases that there was no merit in the petitioners’ 
second causation theory that thimerosal vaccines alone can cause autism. The 
proceedings in these six test cases are concluded, and those petitioners remaining in 
the OAP must now decide whether to pursue their cases by submitting new evidence 
on causation, or take other action to exit the Program.
26
 Other theories of causation 
are being advanced in individual cases, but there are no new test cases planned.
27
 
 
                                                 
23
 The OAP was established by the Chief Special Master of the US Court of Federal Claims: see 
Autism General Order # 1 2002 WL31696785, 2002 US Claims LEXIS 365 (Fed Cl Spec Mstr July 3, 
2002). 
24
 Sayers v Smithkline Beecham Plc, Smith Kline & French Laboratories Ltd, Merck & Co Inc, Sanofi 
Pasteur MSD Ltd [2007] EWHC 1346, QB.  
25
 The PSC has now disbanded, and the remaining cases will be resolved on a firm-by-firm or 
individual basis, without PSC input or participation: In Re: Claims for Vaccine Injuries Resulting in 
Autism Spectrum Disorder or a Similar Neurodevelopmental Disorder, Various Petitioners v Secretary 
of Health and Human Services, Autism Update, January 12, 2011, 2. 
26
 ibid 3. 
27
 ibid 4. 
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B. The First Three Test Cases and the Petitioners’ First Theory 
(i). The First Three Test Cases 
The United States Vaccine Court Omnibus Autism Proceeding under the NVIA gave 
three rulings in the three test cases where the petitioners claimed that measles-mumps-
rubella vaccines combined with thimerosal-containing vaccines administered to three 
children had caused several conditions, including autism
28
 and chronic gastrointestinal 
symptoms. The key question under the National Vaccine Injury Compensation 
Program is the establishment of a causal link between the vaccination and the injury. 
In some cases the petitioner may simply demonstrate the occurrence of a so-called 
Table Injury, ie that the vaccine recipient was administered a vaccine and suffered an 
injury covered by the NVIA, occurring within an applicable time period following the 
vaccination specified in the Vaccine Injury Table.
29
 If so, the Table Injury is 
presumed to have been caused by the vaccination.
30
 However, in the Omnibus Autism 
Proceeding, each of the petitioners’ test cases was based on an exception to the Table. 
Here, the petitioners claimed that they suffered injuries not of the type covered in the 
Table, but that they could show by a preponderance of evidence that their injuries 
were ‘caused-in-fact’ by the vaccination in question.31 This is known as an off-Table 
injury or causation-in-fact claim. In contrast to the relaxation of the burden of proving 
causation for injuries satisfying the Table, the burden of proof on the petitioner in a 
causation-in-fact claim is a heavy one.
32
 
Essentially, the three test cases, Cedillo,
33
 Snyder
34
 and Hazlehurst,
35
 were 
three of more than 5,000 cases filed with the National Vaccine Injury Compensation 
Program, in which it has been alleged that autism or a similar disorder was caused by 
one or more vaccines. The evidentiary record was described by the Special Master in 
                                                 
28
 In the Omnibus Proceeding, it was noted that the terms ‘autism’, ‘autistic’ and ‘autism spectrum 
disorder’ would interchangeably be used to refer to the entire group of disorders within the category of 
‘pervasive developmental disorder’ (PDD).  
29
 42 USC § 300aa-11(c)(1)(C)(i). 
30
 42 USC § 300aa-11(c)(1)(C)(i); § 300aa-13(a)(1)(A). 
31
 42 USC § 300aa-11(c)(1)(C)(ii)(I); § 300aa-13(a)(1)(A); Moberly v Secretary of Health & Human 
Services 592 F 3d 1315, 1322 (Fed Cir 2010); Shyface v Secretary of Health & Human Services 165 F 
3d 1344, 1352–53 (Fed Cir 1999); Hines v Secretary of Health & Human Services 940 F 2d 1518, 1525 
(Fed Cir 1991). 
32
 Grant v Secretary of Dept of Health & Human Services 956 F 2d 1144, 1148 (Fed Cir 1992); Hodges 
v Secretary of Dept of Health & Human Services 9 F 3d 958, 961 (Fed Cir 1993). Nonetheless, it has 
been judicially observed that Congress ‘clearly intended’ that its goal of rendering expeditious, certain 
and generous determinations should apply equally to Table and off-Table claims: Stevens v Secretary of 
HHS, No 99-594 V, 2001 WL 387418 (Fed Cl Mar 30, 2001) at *7, Chief Special Master Golkiewicz 
(noting the difficulties associated with causation in fact cases under the National Childhood Vaccine 
Injury Compensation Program); HR Rep No 99-908, 13; see further, KE Strong, Note, ‘Proving 
Causation Under the Vaccine Injury Act: A New Approach for a New Day’ (2007) 75 George 
Washington Law Review 426, 442–46 (submitting that the medical and scientific uncertainties 
surrounding vaccine injuries, as well as the lack of a uniform standard for causation in fact cases, has 
meant that the goals of Congress have not been met for petitioners who require to prove off-Table 
claims).   
33
 Cedillo v Secretary of Health & Human Services, 98-916V, 2009 WL 331968 (Fed Cl Feb 12, 2009), 
aff’d, 89 Fed Cl 158, 164, 184 (2009), aff’d, 617 F 3d 1328, 1334, 1349–50 (Fed Cir 2010). 
34
 Snyder v Secretary of Health & Human Services, 01-162V, 2009 WL 332044 (Fed Cl Feb 12, 2009), 
aff’d, 88 Fed Cl 706, 708, 748 (2009).  
35
 Hazlehurst v Secretary of Health & Human Services, 03-654V, 2009 WL 332306 (Fed Cl Feb 12, 
2009), aff’d, 88 Fed Cl 473, 475, 490 (2009), aff’d, 604 F 3d 1343, 1345, 1354 (Fed Cir 2010). 
 7 
Cedillo as ‘massive’,36 and one which dwarfed, by far, any evidentiary record in any 
Program case. The amount of medical literature filed in records of the three cases was 
noted as being ‘staggering’.37 During the evidentiary hearings, a total of 28 expert 
witnesses testified. A total of 939 different items of medical literature were filed in 
the three cases, the complexity of the material involving many different specialities of 
biology and medicine, including neurology, gastroenterology, virology, immunology, 
molecular biology, toxicology, genetics and epidemiology.
38
   
(ii) The First General Causation Theory 
The petitioners advanced a causation theory which had several parts, including three 
main contentions, viz: (1) that thimerosal-containing vaccines can cause immune 
dysfunction; (2) that the MMR vaccine can cause autism; and (3) that the MMR 
vaccine can cause gastrointestinal dysfunction.
39
 It was agreed that the Petitioners’ 
Steering Committee (PSC) would present its general causation evidence concerning 
the first theory, along with all the evidence specific to the Cedillo case.
40
 As to each 
of the general causation theory elements, Special Master Hastings concluded that ‘the 
evidence was overwhelmingly contrary to the petitioners’ contentions’.41 
Considerable emphasis was placed on the respondent’s expert witnesses, who were 
‘far better qualified, far more experienced and far more persuasive than the 
petitioners’ experts concerning most of the key points’.42 The numerous medical 
studies came down strongly against the petitioners’ contentions. Having considered 
all the evidence, the Special Master found that the petitioners had failed to 
demonstrate that thimerosal-containing vaccines in general could contribute to 
causing immune dysfunction or that the MMR vaccine could contribute to causing 
either autism or gastrointestinal dysfunction.
43
  
The petitioners’ general causation theory concerning the causation of autism 
was contingent on a weakening of the immune system by thimerosal-containing 
                                                 
36
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *14. 
37
 ibid at *14–15. 
38
 ibid. For a comprehensive discussion of the early stages of the Omnibus Autism Proceeding prior to 
the decisions in the test cases being decided, as well as discussion of potential problems in the 
aftermath of the Proceeding, see, G Shemin, ‘Mercury Rising: The Omnibus Autism Proceeding and 
What Families Should Know Before Rushing Out of Vaccine Court’ (2008) 58 American University 
Law Review 459.  
39
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *1. 
40
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *10. 
Then, over the following months, the PSC would present its case-specific evidence concerning the two 
additional test cases, viz, Snyder v Secretary of Health & Human Services, 01-162V, 2009 WL 332044 
(Fed Cl Feb 12, 2009) and Hazlehurst v Secretary of Health & Human Services, 03-654V, 2009 WL 
332306 (Fed Cl Feb 12, 2009): ibid. 
41
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *1. See, 
also, Snyder v Secretary of Health & Human Services, 01-162V, 2009 WL 332044 (Fed Cl Feb 12, 
2009) at *1, Special Master Vowell.  
42
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *1. See 
also Snyder v Secretary of Health & Human Services, 01-162V, 2009 WL 332044 (Fed Cl Feb 12, 
2009) at *1, Special Master Vowell (stating that ‘it was abundantly clear that petitioners’ theories of 
causation were speculative and unpersuasive’); and Hazlehurst v Secretary of Health & Human 
Services, 03-654V, 2009 WL 332306 (Fed Cl Feb 12, 2009) at *13.  
43
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *1. See 
also Snyder v Secretary of Health & Human Services, 01-162V, 2009 WL 332044 (Fed Cl Feb 12, 
2009) at *1, *76, *104, *137; Hazlehurst v Secretary of Health & Human Services, 03-654V, 2009 WL 
332306 (Fed Cl Feb 12, 2009) at *85, *150, *171. 
 8 
vaccines which allowed the measles virus contained in the MMR vaccine to persist 
within the child’s body.44 However, the determination by the Special Masters in all 
three cases that the testing for the presence of the measles virus in the intestinal tissue 
of Cedillo, Snyder and Hazlehurst and other autistic children was unreliable
45
 was 
fatal to all three decisions.  
The petitioners’ general theory concerning the causation of autism was 
rejected on the basis of nine grounds, viz: 
(1) the general theory depended upon the existence of reliable laboratory test 
findings of persisting measles virus, but such a reliable test did not exist;
46
  
(2) the available evidence did not demonstrate any substantial likelihood that 
measles virus persistence in the brain would cause autism;
47
  
                                                 
44
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *15; 
Snyder v Secretary of Health & Human Services, 01-162V, 2009 WL 332044 (Fed Cl Feb 12, 2009) at 
*28; Hazlehurst v Secretary of Health & Human Services, 03-654V, 2009 WL 332306 (Fed Cl Feb 12, 
2009) at *86. The Special Master in Hazlehurst summarised the theory of causation as follows: 
‘Specifically, petitioners assert that the measles component of the MMR vaccine causes an immune 
dysfunction that impairs the vaccinee’s ability to clear the measles virus. Unable to clear properly … 
the measles virus from the body, the vaccinee experiences measles virus persistence which leads to 
chronic inflammation in the gastrointestinal system and, in turn, chronic inflammation in the brain. 
Petitioners argue that the inflammation in the brain causes neurological damage that manifests as 
autism. It is also the position of petitioners that the viral persistence is facilitated by the vaccinee’s 
receipt of thimerosal containing vaccines that suppress the immune system of the vaccinee and impair 
the immune system’s ability to respond properly to the viral presence’: ibid at *86. 
45
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *29–
59, aff’d, 89 Fed Cl 158, 171–72 (2009), aff’d 617 F 3d 1328, 1345 (Fed Cir 2010); and, further, 
Snyder v Secretary of Health & Human Services, 01-162V, 2009 WL 332044 (Fed Cl Feb 12, 2009) at 
*116; Hazlehurst v Secretary of Health & Human Services, 03-654V, 2009 WL 332306 (Fed Cl Feb 
12, 2009) at *150. The studies purported to find the presence of the measles virus in the biological 
material of autistic children and primarily derived from two sources: the work of Dr Andrew Wakefield 
of the Royal Free Hospital in London (see, in particular, his article, AJ Wakefield, et al, ‘Ileal-
lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children’ 
[retracted] (1998) 351 Lancet 637–41), and his colleagues John O’Leary and Orla Sheils at the for 
profit, non-accredited Unigenetics laboratory in Dublin; and the research of Dr Stephen Walker of 
Wake Forest University School of Medicine, North Carolina. Dr Wakefield and his colleagues were 
‘the principle proponents of the hypothesis that the receipt of the MMR vaccine results in the 
development of autism spectrum disorders and gastrointestinal problems in certain children’: 
Hazlehurst v Secretary of Health & Human Services, 03-654V, 2009 WL 332306 (Fed Cl Feb 12, 
2009) at *87, *126. The Special Master found that the work of Dr Wakefield had been largely 
discredited and that none of the studies indicating the presence of the measles virus in autistic children 
had been successfully replicated independently of Wakefield or Unigenetics: ibid at *90, 124. The 
testimony of a government expert, Professor Stephen Bustin (who had also been an expert for the 
vaccine manufacturers in the UK MMR litigation) helped to discredit the reliability of the testing 
conducted at Unigenetics: ibid at *129–32. It was held on appeal that this testimony had been properly 
admitted: Hazlehurst v Secretary of Health & Human Services 88 Fed Cl 473, 480–83 (2009), aff’d, 
604 F 3d 1343, 1349–50 (Fed Cir 2010). Shortly before the first test case, Cedillo, was due to begin, 
the Secretary of Health and Human Services was granted permission to obtain from the records of the 
High Court, copies of expert witness reports of Professors Bustin, Simmonds and Rima, filed by the 
defendants in the UK MMR/MR Vaccine Litigation, so as to use these documents in the Omnibus 
Autism Proceedings in the US: Sayers v Smithkline Beecham Plc, Smith Kline & French Laboratories 
Ltd, Merck & Co Inc, Sanofi Pasteur MSD Ltd [2007] EWHC 1346 (QB).  
46
 ibid at *67–68. 
47
 ibid at *67–69. 
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(3) the evidence indicated that the wild measles virus had never been shown to 
cause autism, which made it quite unlikely that the vaccine strain form of the 
measles virus could cause autism;
48
  
(4) the petitioners’ theory seemed unlikely in the light of several accepted 
understandings concerning the causation of autism, in particular that there was 
a very strong genetic component to the causation of autism;
49
   
(5) there were contradictions and inconsistencies in the testimony concerning the 
appropriate time period between the MMR vaccination and the onset of autism 
symptoms;
50
 
(6) the testimony of three other experts failed to provide substantial support to the 
causation theory of the petitioners’ expert Dr Kinsbourne;51 
(7) the qualifications of the respondent’s experts concerning this issue 
substantially exceeded the qualifications of the petitioners’ expert witnesses;52 
(8) the epidemiologic evidence consisting of numerous studies by qualified 
medical researchers around the world
53
 added another reason to reject the 
petitioners’ theory that vaccines could contribute to the causation of autism;54 
and  
                                                 
48
 ibid at *67, *69–71. 
49
 ibid at *67, * 71–77. 
50
 ibid at *67, *77–79. 
51
 ibid at *67, *79–83. 
52
 ibid at *67, *83–84. 
53
 See B Taylor, et al, ‘Autism and Measles, Mumps, and Rubella Vaccine: No Epidemiological 
Evidence for a Causal Association’ (1999) 353 Lancet 2026–29; F DeStefano, et al, ‘Age at First 
Measles-Mumps-Rubella Vaccination in Children With Autism and School-Matched Control Subjects: 
A Population-Based Study in Metropolitan Atlanta’ (2004) 113 Pediatrics 259–66; L Smeeth, et al, 
‘MMR Vaccination and Pervasive Developmental Disorders: A Case-Control Study’ (2004) 364 
Lancet 963–69; B Taylor, et al, ‘Measles, Mumps, and Rubella Vaccination and Bowel Problems or 
Developmental Regression in Children with Autism: Population Study’ (2002) 324 British Medical 
Journal 393–96; CP Farrington, et al, ‘MMR and Autism: Further Evidence Against a Causal 
Association’ (2001) 19 Vaccine 3632–35; E Fombonne and S Chakrabarti, ‘No Evidence for a New 
Variant of Measles-Mumps-Rubella-Induced Autism’ (2001) 108 Pediatrics e58; S Dewilde, ‘Do 
Children Who Become Autistic Consult More Often After MMR Vaccination?’, (2001) 51 British 
Journal of General Practice 226–27; A Mӓkelӓ, et al, ‘Neurologic Disorders After Measles-Mumps-
rubella Vaccination’ (2002) 110 Pediatrics 957–63; H Takahashi, et al, ‘An Epidemiological Study on 
Japanese Autism Concerning Routine Childhood Immunization History’ (2003) 56 Japanese Journal of  
Infectious Diseases 114–17; W Chen, et al, ‘No Evidence for Links Between Autism, MMR and 
Measles Virus’ (2004) 34 Psychological Medicine 543–53; H Honda, et al, ‘No Effect of MMR 
Withdrawal on the Incidence of Autism: A Total Population Study (2005) 46 Journal of Child 
Psychology and Psychiatry 572–79.   
54
 ibid at *67, *92–93. Special Master Hastings effectively destroyed the sufficiency of the 
epidemiologic evidence proffered by the petitioners in the following two paragraphs:  
‘The numerous epidemiologic studies done over the past ten years, when taken together, make it very 
unlikely that the MMR vaccination has played any significant role in the overall causation of autism. It 
is true, as the petitioners argue, that the available epidemiologic studies do not completely rule out the 
possibility that the MMR vaccine might be associated with some small subset of autism, such as 
regressive autism. However, there are three reasons why the epidemiologic evidence still must be said 
to provide significant evidence against the petitioners’ general causation theory set forth in this case. 
First, none of the numerous competent studies has yielded the slightest bit of evidence in the 
petitioners’ favor. Second, the failure of so many studies to find any association between MMR 
vaccine and autism, while not completely ruling out a possible causal role with respect to a subset of 
autism, at least casts considerable doubt upon the proposition that the MMR vaccine ever plays a role 
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(9) Two reports of well-qualified experts published by the Institute of Medicine in 
2001 and 2004 studied the general MMR/autism causation issue and 
concluded that the evidence favoured rejection of the proposition that the 
MMR vaccine could cause autism.
55
    
Taken together, all this evidence was irrefutable.  
C. The Second Three Test Cases and the Petitioners’ Second Theory 
(i) The Second Three Test Cases 
The Petitioners Steering Committee’s second causation theory was that thimerosal-
containing vaccines alone can cause autism.
56
 The same three Special Masters who 
had been tasked with hearing the first three test cases concerning the first theory of 
general causation were also tasked with hearing the second three test cases concerning 
the second theory of general causation advanced by the petitioners.
57
 The evidentiary 
record was described as ‘massive’,58 and one which exceeded any evidentiary record 
in any Program case, with the exception of the record in the first three test cases. 
During the evidentiary hearings, a total of 26 expert witnesses testified. The amount 
of medical literature filed into the records of the three cases was a ‘staggering’ figure 
of more than 1200 different items.
59
 In March 2010, each of the three Special Masters 
issued a decision in the test case assigned to them, ie respectively in Mead,
60
 Dwyer
61
 
and King.
62
 All three Special Masters found that the parents had failed to prove that 
their children’s autism was caused by the thimerosal-containing vaccines that they 
received.
63
 
                                                                                                                                            
in causing any kind of autism, including regressive autism. And, third, five studies provide evidence 
that is directly relevant to the petitioners’ “regressive autism only” argument, supplying significant 
evidence against the theory that the MMR vaccine plays a causal role even in the subset of autism 
known as regressive autism. 
Accordingly, my conclusion is that the epidemiologic evidence does provide yet another strong reason 
to reject the petitioners’ general causation theory presented in this case’: ibid at* 92–93. 
55
 ibid at *68, *93–94; see Institute of Medicine, Immunization Safety Review: Measles-Mumps-Rubella 
Vaccine and Autism (Washington DC, The National Academies Press, 2001), p 60; Institute of 
Medicine, Immunization Safety Review: Vaccines and Autism (Washington DC, The National 
Academies Press, 2004) 7, 16, 126, 151–52. 
56
 Mead v Secretary of Health & Human Services, 03-215V, 2010 WL 892248 (Fed Cl March 12, 
2010) at *2. 
57
 Mead v Secretary of Health & Human Services, 03-215V, 2010 WL 892248 (Fed Cl March 12, 
2010) at *4. 
58
 King v Secretary of Health & Human Services, 03-584V, 2010 WL 892296 (Fed Cl March 12, 2010) 
at *12. 
59
 ibid. 
60
 Mead v Secretary of Health & Human Services, 03-215V, 2010 WL 892248 (Fed Cl March 12, 
2010). 
61
 Dwyer v Secretary of Health & Human Services, 03-1202V, 2010 WL 892250 (Fed Cl March 12, 
2010). 
62
 King v Secretary of Health & Human Services, 03-584V, 2010 WL 892296 (Fed Cl March 12, 2010). 
63
 Mead v Secretary of Health & Human Services, 03-215V, 2010 WL 892248 (Fed Cl March 12, 
2010) at *1, 13, 113; Dwyer v Secretary of Health & Human Services, 03-1202V, 2010 WL 892250 
(Fed Cl March 12, 2010) at *1–2, 201; King v Secretary of Health & Human Services, 03-584V, 2010 
WL 892296 (Fed Cl March 12, 2010) at *1, 90–91. 
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(ii) The Second General Causation Theory 
The petitioners’ medical theory contended that ‘the thimerosal component of the 
received childhood vaccines dissociates into organomercurial ethylmercury once in 
the body’.64 That ethylmercury ‘then courses through the blood stream to diffuse 
across the blood-brain barrier to reach the brain’.65 On reaching the brain, ‘the 
ethylmercury is de-ethylated to become inorganic mercury – a form of mercury that is 
not quickly removed from the brain – and once deposited, provokes a series of 
detrimental responses that ultimately manifest as autism’.66 It was found that the 
underpinnings for the opinions of the petitioners’ experts concerning the second 
theory were ‘scientifically flawed’, and in the absence of a sound basis for the offered 
opinions of causation, these opinions ‘[could not] be credited’.67 The theory that the 
thimerosal content of the vaccines contributed to the development of autism was 
‘scientifically unsupportable’.68  
Several epidemiological studies
69
 were examined and it was found that they 
showed no association between thimerosal-containing vaccines and the development 
of autistic spectrum disorders.
70
 Reference was made to the evidence given by the 
                                                 
64
 Mead v Secretary of Health & Human Services, 03-215V, 2010 WL 892248 (Fed Cl March 12, 
2010) at *106; and further, at *17. 
65
 ibid. 
66
 ibid. 
67
 Mead v Secretary of Health & Human Services, 03-215V, 2010 WL 892248 (Fed Cl March 12, 
2010) at *109, citing Perreira v Secretary of Health & Human Services 33 F 3d 1375, 1377 fn 6 (Fed 
Cir 1994) (‘An expert opinion is no better than the soundness of the reasons supporting it’). 
68
 Mead v Secretary of Health & Human Services, 03-215V, 2010 WL 892248 (Fed Cl March 12, 
2010) at *113; see, further, Dwyer v Secretary of Health & Human Services, 03-1202V, 2010 WL 
892250 (Fed Cl March 12, 2010) at *165, 198–99; King v Secretary of Health & Human Services, 03-
584V, 2010 WL 892296 (Fed Cl March 12, 2010) at *34–35. 
69
 See A Hviid, et al, ‘Association Between Thimerosal-Containing Vaccine and Autism’ (2003) 290 
Journal of American Medical Association 1763–66; K Madsen, et al, Thimerosal and the Occurrence of 
Autism: Negative Ecological Evidence From Danish Population-Based Data (2003) 112 Pediatrics 
604–6; T Verstraeten, et al, ‘Safety of Thimersoal-Containing Vaccines: A Two Phased Study of 
Computerized Health Maintenance Organinzation Databases’ (2003) 112 Pediatrics 1039–48; P Stehr-
Green, et al, ‘Autism and Thimerosal-Containing Vaccines’ (2003) 25 American Journal of 
Preventative Medicine 101–6; N Andrews, et al, ‘Thimerosal Exposure in Infants and Developmental 
Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal 
Association’ (2004) 114 Pediatrics 584–91; H Jick and J Kaye, ‘Autism and DPT Vaccination in the 
United Kingdom’ (2004) 350 New England Journal of Medicine 2722–23; E Fombonne, et al, 
‘Pervasive Development Disorders in Montreal, Quebec, Canada: Prevalence and Links with 
Immunizations’ (2006) 118 Pediatrics e139–50; R Schechter and J Grether, ‘Continuing Increases in 
Autism Reported to California’s Developmental Services System’ (2008) 65 Archives of General 
Psychiatry 19–24. Two other studies did not directly address the question of an association between 
thiomersal and autism, but provided relevant information: (see J Heron and J Golding, ‘Thimerosal 
Exposure in Infants and Developmental Disorders: A Prospective Cohort Study in the United Kingdom 
Does Not Support a Causal Association’ (2004) 114 Pediatrics 577–83; and WW Thompson, et al, 
‘Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years’ (2007) 357 New 
England Journal of Medicine 1281–92). In the light of the strength of the epidemiological evidence of 
no association, and given the absence of any direct evidence for a biological mechanism, the Institute 
of Medicine concluded that the evidence favoured rejection of a causal association between thimerosal-
containing vaccines and autism: Institute of Medicine, Immunization Safety Review: Vaccines and 
Autism (Washington DC, The National Academies Press, 2004) 16, 151–52. 
70
 Mead v Secretary of Health & Human Services, 03-215V, 2010 WL 892248 (Fed Cl March 12, 
2010) at *39. See, further, Dwyer v Secretary of Health & Human Services, 03-1202V, 2010 WL 
892250 (Fed Cl March 12, 2010) at *77 (‘In this case, the epidemiological studies furnish powerful 
evidence refuting a causal association between TCVs [thimerosal-containing vaccines] and ASD’); and 
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eminent paediatric psychiatrist, Professor Sir Michael Rutter who, having examined 
the limitations of the epidemiological studies, had concluded that ‘taken as whole, the 
studies were all “unsupportive of a causal association”’.71  
D. Implications of the Test Cases 
(i) Epidemiological Evidence Should be Given Appropriate Weight  
Some of the most significant evidence used to reject the general causation theory were 
the numerous epidemiologic studies performed over the previous 10 years which, 
when taken together, made it very unlikely that the MMR vaccination played a 
significant role in the overall causation of autism.
72
 Both the Cedillo and King test 
cases, determined by Special Master Hastings, clarify the position surrounding the use 
of such epidemiological evidence supporting a causation-in-fact claim under the 
National Vaccine Injury Compensation Program (the Program). They reaffirm the 
settled legal position that while there is no requirement that epidemiological evidence 
supports a causation-in-fact claim under the Program,
73
 in the relatively rare instance 
in which general causation has been the subject of published epidemiological studies, 
such evidence should be given appropriate weight, along with the other evidence of 
the record.
74
  
                                                                                                                                            
King v Secretary of Health & Human Services, 03-584V, 2010 WL 892296 (Fed Cl March 12, 2010) at 
* 66–67. While the petitioners conceded through their expert, Professor Sander Greenland, that the 
epidemiologic literature to date had not detected an association of mercury-containing vaccines and 
autism in general or autistic spectrum disorders, Dr Greenland claimed that the performed 
epidemiological studies lacked the requisite specificity to detect an association between the receipt of 
thimerosal-containing vaccines and regressive autism: Mead v Secretary of Health & Human Services, 
03-215V, 2010 WL 892248 (Fed Cl March 12, 2010) at *41–45. This position presumed that regressive 
autism was a distinct phenotype of autism. However, the Special Master found that studies of the 
developmental patterns in children described as having early onset autism and in children described as 
having regressive autism, militated against a finding that regression in autism constituted a separate 
phenotype of autistic disorder: ibid at *45,112; and further, Dwyer v Secretary of Health & Human 
Services, 03-1202V, 2010 WL 892250 (Fed Cl March 12, 2010) at *62–63 (petitioners failed to 
demonstrate the existence of ‘clearly regressive autism’ as a separate phenotype; Dr Greenland’s 
opinion that the existing epidemiologic studies could not rule out a substantial causal rule for 
thimerosal-containing vaccines in one form of autism was ‘not relevant or persuasive’); and King v 
Secretary of Health & Human Services, 03-584V, 2010 WL 892296 (Fed Cl March 12, 2010) at *39 
70–72. When the results of the epidemiological studies were viewed as a whole, they were found to 
reach the consistent conclusion that there was no association between thimerosal-containing vaccines 
and autism: Mead v Secretary of Health & Human Services, 03-215V, 2010 WL 892248 (Fed Cl March 
12, 2010) at *45; King v Secretary of Health & Human Services, 03-584V, 2010 WL 892296 (Fed Cl 
March 12, 2010) at *75. 
71
 ibid at *40.  
72
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *123.  
73
 Capizzano v Secretary of Health & Human Services 440 F 3d 1317, 1325–26 (Fed Cir 2006). Indeed, 
causation can be demonstrated under the Programme without any support from medical literature: 
Althen v Secretary of Health & Human Services 418 F 3d 1274, 1281 (Fed Cir 2005). 
74
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *92; 
King v Secretary of Health & Human Services, 03-584V, 2010 WL 892296 (Fed Cl March 12, 2010) at 
*74. See, further, Hazlehurst v Secretary of Health & Human Services, 03-654V, 2009 WL 332306 
(Fed Cl Feb 12, 2009) at *39; Terran v Secretary of Health & Human Services 195 F 3d 1302, 1315–17 
(Fed Cir 1999); Grant v Secretary of Health & Human Services 956 F 2d 1144, 1149 (Fed Cir 1992). 
Epidemiologic evidence should be considered in evaluating scientific theories: Scott v Secretary of 
Health & Human Services, 03-2211V, 2006 WL 2559776 at *21; Garcia v Secretary of Health & 
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(ii) Reliability of Expert Testimony 
Crucial to the determination of these test cases are the factors that a Special Master is 
required to consider in evaluating the reliability of expert testimony and other 
scientific evidence relating to causation. Even though the Federal Rules of Evidence 
do not apply in Program cases,
75
 the test cases reaffirm that it is appropriate to use the 
Daubert
76
 factors as a tool or framework for conducting the inquiry into the reliability 
of causation in fact theories.
77
 In particular, two of the important factors listed in 
Daubert and utilised by the Special Masters in evaluating these theories
78
 were 
whether the scientific theory had been subject to peer review or publication and also 
whether the theory or technique enjoyed general acceptance.
79
 Such epidemiological 
evidence, while not dispositive, should be considered in evaluating scientific theories, 
such as the general causation theory in issue in the test cases.
80
  
                                                                                                                                            
Human Services, 05-720V, 2008 WL 5068934, at *3, *10. The reliance of a Special Master on 
epidemiologic evidence has been subject to express approval: see, eg, Moberly v Secretary of Health & 
Human Services 85 Fed Cl 571, 596 (2009), aff’d, 592 F 3d 1315, 1325 (Fed Cir 2010); Estep v 
Secretary of Health & Human Services 28 Fed Cl 664, 668 (1993); Sharpnack v Secretary of Health & 
Human Services 27 Fed Cl 457, 459 (1993); Sumrall v Secretary of Health & Human Services 23 Cl Ct 
1, 8 (1991); Hennessey v Secretary of Health & Human Services, 01-190V, 2010 WL 94560, at *6–7, 
*11–13.   
75
 42 USC §300aa-12(d)(2)(B): Vaccine Rules ‘shall include flexible informal studies of admissibility 
of evidence’. 
76
 Daubert v Merrill Dow Pharmaceuticals, Inc 509 US 579, 593–94 (1993); and, further, General 
Electric Co v Joiner, 522 US 136, 139, 141, 143, 146 (1997); Kumho Tire Co v Carmichael, 526 US 
137, 147–49, 152–53 (1999); Weisgram v Marley Co 528 US 440, 456–57 (2000); Fed. R. Evidence 
Rule 702, 28 USCA; Fed. R. Evidence 702 Advisory Committee’s Note (2000 Amendment); see DG 
Owen, Products Liability Law, 2nd edn (St Paul, MN Thomson/West, 2008) § 6.3. For criticism that 
Daubert and its progeny have in some cases hindered the search for justice in product liability law, see, 
generally, C Cranor, Toxic Torts: Science, Law, and the Possibility of Justice (Cambridge University 
Press, 2007) and, in particular, ibid 337, 340–41, 348, 353, 356, 368. 
77
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *3; 
aff’d, 89 Fed Cl 158, 182 (2009), aff’d 617 F 3d 1328, 1338–38 (Fed Cir 2010), (applying Terran v 
Secretary of Health & Human Services 195 F 3d 1302, 1316 (Fed Cir 1999)); Snyder v Secretary of 
Health & Human Services, 01-162V, 2009 WL 332044 (Fed Cl Feb 12, 2009) at *30, *138, *194, aff’d 
88 Fed Cl 706, 736, 744–45 (2009); Hazlehurst v Secretary of Health & Human Services, 03-654V, 
2009 WL 332306 (Fed Cl Feb 12, 2009) at *16–17; aff’d, 88 Fed Cl 473, 483 (2009), aff’d, 604 F 3d 
1343, 1353 (Fed Cir 2010); Mead v Secretary of Health & Human Services 03-215V, 2010 WL 892248 
(Fed Cl March 12, 2010) at *13–15; Dwyer v Secretary of Health & Human Services, 03-1202V, 2010 
WL 892250 (Fed Cl March 12, 2010) at *7, 25–26 ; King v Secretary of Health & Human Services, 03-
584V, 2010 WL 892296 (Fed Cl March 12, 2010) at *3, 73. For further approval of the utilisation of 
the Daubert factors in evaluating the reliability of scientific evidence in cases under the Program, see 
Moberly v Secretary of Health & Human Services 592 F 3d 1315, 1324 (Fed Cir 2010); Andreu v 
Secretary of Health & Human Services 569 F 3d 1367, 1379 (Fed Cir 2009); Knudsen v Secretary of 
Health & Human Services 35 F 3d 543, 548 (Fed Cir 1994); Perreira v Secretary of Health & Human 
Services 33 F 3d 1375, 1377 fn 6 (Fed Cir 1994).  
78
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *3. 
79
 Daubert v Merrill Dow Pharmaceuticals, Inc 509 US 579, 593–94 (1993). 
80
 Terran v Secretary of Health & Human Services 195 F 3d 1302, 1315–17 (Fed Cir 1999); Grant v 
Secretary of Health & Human Services 956 F 2d 1144, 1149 (Fed Cir 1992); Scott v Secretary of 
Health & Human Services, 03-2211V, 2006 WL 2559776 at *21; Garcia v Secretary of Health & 
Human Services, 05-720V, 2008 WL 5068934, at *3, *10; King v Secretary of Health & Human 
Services, 03-584V, 2010 WL 892296 (Fed Cl March 12, 2010) at *74. 
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(iii) The Causation-in-Fact Standard: General and Specific Causation and 
Temporal Proximity 
One of the most interesting aspects of the test cases is their utilisation of the 
causation-in-fact standard. The cases emphasise the importance of establishing both 
general and specific causation in vaccine damage cases, as well as the need for 
temporal proximity between the vaccine and the damage in each case. This legal 
standard of proof for causation in fact under the Program was elaborated on in the 
leading case of Althen v Secretary of Health & Human Services.
81
 There, the Federal 
Circuit established three factors which had to be satisfied to overcome the burden of 
proof, viz: (1) a medical theory causally connecting the vaccination and the injury; (2) 
a logical sequence of cause and effect showing that the vaccination was the reason for 
the injury; and (3) a showing of a proximate temporal relationship between the 
vaccination and the injury.
82
 In all six test cases in the Omnibus Autism Proceeding, 
the Special Masters were able to explain how their analyses of the petitioners’ 
contentions on the scientific evidence fitted within the three prongs of the test and 
how in each case none of the requirements of the three factors were satisfied.
83
 
The principal test case of the first general causation theory, Cedillo, provides 
an important explanation of the three prongs of the Althen test. The first prong, viz the 
requirement of a medical theory causally connecting the vaccination and the injury is 
explained as a general causation requirement, ie that the type of vaccination in 
question can cause the type of injury in question. The second prong, a logical 
sequence of cause and effect showing that the vaccination was the reason for the 
injury, is explained as a specific causation requirement, ie that the particular 
vaccination received by the specific vaccinee did cause the vaccinee’s own injury. 
Cedillo affirms the ‘can/did cause’ test, as being equivalent to the first two prongs of 
Althen.
84
 Applying the available scientific evidence, the Special Master held that the 
petitioners’ arguments fell far short of demonstrating that the MMR vaccination could 
contribute in general to the causation of either autism or chronic gastrointestinal 
dysfunction, or that the MMR vaccination did contribute to the causation of Cedillo’s 
own autism and gastrointestinal symptoms.
85
 Moreover, there was no doubt that the 
Althen test required that as an overall matter, a petitioner had to demonstrate that it 
                                                 
81
 Althen v Secretary of Health & Human Services 418 F 3d 1274 (Fed Cir 2005). 
82
 ibid 1278. 
83
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *132–
33; aff’d, 89 Fed Cl 158, 182–83 (2009); For discussion of the application of the Althen test in the other 
two test cases of the first general causation theory, see Snyder v Secretary of Health & Human 
Services, 01-162V, 2009 WL 332044 (Fed Cl Feb 12, 2009) at *29, *192–98, aff’d 88 Fed Cl 706, 
745–46 (2009) and Hazlehurst v Secretary of Health & Human Services, 03-654V, 2009 WL 332306 
(Fed Cl Feb 12, 2009) at *15–19, *83–86. For discussion of the application of the Althen test in the 
three test cases of the second general causation theory, see Mead v Secretary of Health & Human 
Services, 03-215V, 2010 WL 892248 (Fed Cl March 12, 2010) at *15–16, 106–13; Dwyer v Secretary 
of Health & Human Services, 03-1202V, 2010 WL 892250 (Fed Cl March 12, 2010) at *23–24, 196–
201; King v Secretary of Health & Human Services, 03-584V, 2010 WL 892296 (Fed Cl March 12, 
2010) at *87–89. 
84
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *131, 
affirming Pafford v Secretary of Health & Human Services 451 F 3d 1352, 1355–56 (Fed Cir 2006); 
and, further, in respect of the second general causation theory, Dwyer v Secretary of Health & Human 
Services, 03-1202V, 2010 WL 892250 (Fed Cl March 12, 2010) at *197; King v Secretary of Health & 
Human Services, 03-584V, 2010 WL 892296 (Fed Cl March 12, 2010) at *87.  
85
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *132; 
aff’d, 89 Fed Cl 158, 182–83 (2009); aff’d 617 F 3d 1328, 1338 (Fed Cir 2010). 
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was more probable than not that the particular vaccine was a substantial contributing 
factor in causing the particular injury in question.
86
 This was clear from the 
‘preponderance of evidence’ standard in the Vaccine Act.87 Regardless of the precise 
meanings of Althen, the overall evidence fell far short of demonstrating that it was 
‘more probable than not’ that the MMR vaccine contributed to the causation of either 
Cedillo’s autism or gastrointestinal symptoms.88 The petitioners also failed to satisfy 
the third element of Althen, viz the need to show a ‘proximate temporal relationship 
between vaccination and injury’.89 They were unable to establish that the first 
symptom of autism and/or the first symptoms of the chronic gastrointestinal problems 
occurred within a time-frame consistent with causation by the MMR vaccination in 
question.
90
  
(iv) Looking Beyond the Epidemiology: The Overall Evidence 
A strength of these Omnibus Autism Proceeding test cases is that in determining 
whether the petitioners have demonstrated causation by a preponderance of evidence, 
the Special Masters have looked beyond the epidemiologic evidence to determine 
whether the overall evidence – ie medical opinion and circumstantial evidence and 
other evidence considered as a whole – tipped the balance even slightly in favour of a 
causation showing.
91
 Ultimately, in each case, the overall weight of the evidence was 
overwhelmingly contrary to the petitioners’ causation theories. In respect of general 
causation, the evidence advanced by the petitioners had fallen far short of 
demonstrating a causal link.
92
 
(v) On the Side of Science 
Thus we can conclude that in these important test cases, the Special Masters have 
come down clearly on the side of science, and in doing so have considered the 
evidence overall. Indeed, one master, Special Master George Hastings in Cedillo 
                                                 
86
 ibid. 
87
 ibid, citing § 300aa-13(a)(I)(A). 
88
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *132; 
aff’d, 89 Fed Cl 158, 182–83 (2009); and, further, in respect of the second general causation theory, 
King v Secretary of Health & Human Services, 03-584V, 2010 WL 892296 (Fed Cl March 12, 2010) at 
*88. 
89
 Althen v Secretary of Health & Human Services 418 F 3d 1274, 1278 (Fed Cir 2005). 
90
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *132–
33, aff’d, 89 Fed Cl 158, 182–83 (2009); Pafford v Secretary of Health & Human Services 451 F 3d 
1352, 1358 (Fed Cir 2006) (need for evidence demonstrating petitioner’s injury within medically 
accepted time-frame). cf the view that the OAP reveals the competing policy tensions between 
compensating injured petitioners and upholding the public confidence in vaccines and their use, and 
that these unresolved policy conflicts have revealed a tension that has fallen on the shoulders of the 
Special Masters presiding over the OAP, which is illustrated by Cedillo: LA Binski, ‘Balancing Policy 
Tensions of the Vaccine Act In Light of the Omnibus Autism Proceeding: Are Petitioners Getting a 
Fair Shot at Compensation?’ (2011) 39 Hofstra Law Review 683, 688, 705–10, 715, 720. Binski 
submits that more guidance needs to be given to Special Masters as to how to strike the balance 
between these competing concerns in causation-in-fact cases: ibid 716–20.   
91
 In determining if a petitioner is entitled to compensation, the Special Master is not bound by any 
diagnosis, conclusion, judgment, test result, report, or summary, and in evaluating the weight to be 
afforded to such matters, ‘shall consider the entire record’: 42 USC § 300aa-13(b)(1) (emphasis added). 
92
 Cedillo v Secretary of Health & Human Services, 2009 WL 331968 (Fed Cl Feb 12, 2009) at *134–
35; and, further, in respect of the second general causal theory, King v Secretary of Health & Human 
Services, 03-584V, 2010 WL 892296 (Fed Cl March 12, 2010) at *91. 
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severely criticised those physicians who are supporting a link between MMR and 
autism. He stated that: ‘Unfortunately, the Cedillos have been misled by physicians 
who are guilty of gross medical misjudgment’.93 All of the Special Masters concluded 
that the petitioners had failed to demonstrate that the vaccinations played any role in 
causing autism. 
V. A FRENCH COMPARISON: THE LIBERAL FRENCH 
APPROACH TO HEPATITIS B VACCINE AND 
DEMYELINATING DISEASES USING PRESUMPTIONS OF 
CAUSATION 
A French Comparison 
In contrast to the US, a much more liberal approach to causation appeared to be 
established in France by the Cour de cassation, principally in the context of claims for 
compensation for demyelinating diseases, allegedly caused or exacerbated by 
vaccinations against hepatitis B.  
In 2003, the Cour de cassation held that causation between the hepatitis B 
vaccination and multiple sclerosis could not be established given the absence of 
scientific certainty on the possible link between the vaccine and the disease.
94
 
However, the Cour de cassation shifted its position on 22 May 2008, when it 
acknowledged in a series of five cases concerning hepatitis B in which it was alleged 
to have caused neurological disorders,
95
 and one case concerning two medications that 
were alleged to have caused Lyell’s syndrome,96 that a causal link could be 
established by the presence of ‘serious, precise and concurrent’ presumptions of 
causation. Such presumptions had to be supported by specific causation-related data 
submitted by each specific claimant on a case-by-case basis relating to the claimant’s 
medical history, but not through generalised statistical or probabilistic studies. As a 
result, despite the absence of any scientific and statistical data showing a causal link 
between hepatitis B vaccine and multiple sclerosis or other neurological illnesses, the 
Cour de cassation quashed two
97
 out of five judgments concerning the hepatitis C 
vaccine which had previously dismissed claims for compensation. The decisions were 
quashed on the grounds that the appellate courts had followed ‘a probabilistic 
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approach based exclusively on the lack of scientific and statistical link between 
vaccination and the development of the disease’98 without investigating the specific 
causation-related data submitted by each claimant and whether this constituted 
serious, precise and concurrent presumptions of causation. In one appellate judgment, 
the court had relied on general studies and statistics to determine that there was no 
causal link between hepatitis B and multiple sclerosis. Accordingly, a claim against a 
pharmaceutical producer could not be rejected on the sole basis of the absence of any 
scientific and statistical data showing a causal link between a medicinal product and 
an illness. This decision to allow the claimants to prove a causal link on the basis of 
serious, precise and concordant presumptions of causation was confirmed by the Cour 
de cassation in a judgment of 25 June 2009, where it observed that lower judges 
cannot require an ‘unquestionable scientific proof’.99   
This led to considerable concern from the pharmaceutical industry, since the 
existence of a causal link could no longer be excluded on the basis of an absence of 
general statistical evidence of a causal link between drug and damage. The industry 
became worried that this position had opened the door to compensation for the alleged 
side-effects of medicinal products generally, especially when the Cour de cassation’s 
position conflicted with legal certainty and fairness in the absence of conclusive 
epidemiology. It also appeared unclear in what circumstances trial judges would be 
able to demonstrate the necessary presumption of causation, in cases where there was 
an absence of scientific evidence of general causation.
100
 
The opportunity to confirm what type of facts could potentially give rise to 
serious, precise and concurrent presumptions quickly arose with the judgment of the 
Cour de cassation of 9 July 2009.
101
 In an extremely controversial judgment, the court 
went beyond its previous decisions of 22 May 2008 and 25 June 2009, and upheld a 
judgment by the Court of Appeal of Lyon, granting a patient’s claim against the 
manufacturer of the hepatitis B vaccine, by finding that causation had been proven 
even in the absence of general causation, but where such a causal link could not be 
excluded. The Court of Appeal of Lyon had utilised two factual criteria to establish a 
presumption of a causal link between the vaccination and the development of multiple 
sclerosis, viz (1), a temporal proximity between the vaccine injection and the 
development of the illness; and (2) the absence of other personal risk factors. The 
Cour de cassation held that while scientific evidence had failed to establish a 
statistically significant increase in relative risk of multiple sclerosis following 
vaccination against hepatitis B, nevertheless it could not exclude such a possible link, 
and there existed proximity between the injection and the development of the disease 
and an absence of other individual risk factors, such facts could constitute serious 
precise and concurrent presumptions. From this, a causal link would be inferred 
between the vaccine and the damage.
102
 It is strongly suspected that the purpose of the 
Cour de cassation’s judgment was to adopt the same position as the Conseil d’État in 
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actions brought by individuals subject to compulsory vaccination to prevent hepatitis 
B against the state or other employers.
103
   
However, certain French Courts of Appeal have resisted this controversial 
approach adopted by the Cour de cassation and have continued to refuse to hold 
manufacturers liable where there is an absence of scientific evidence of general 
causation.
104
 In particular, the Paris Court of Appeal stressed the need to base the 
decisions on specific personal data of the claimant, whilst at the same time 
reaffirming the absence of any scientific consensus between hepatitis B vaccine and 
neurological disorders, the fact that that the aetiology is unknown and that multiple 
sclerosis can be caused by various genetic factors.
105
 Moreover, in its judgment of 19 
June 2009, the Paris Court of Appeal held that temporal proximity and the absence of 
personal risk factors did not constitute serious, precise and concurrent 
presumptions.
106
 This position was upheld by the Cour de cassation in its decisions of 
24 September 2009, and 25 November 2010.
107
 Accordingly, the Cour de cassation 
appeared to be retreating somewhat from its position on 9 July 2009. Unfortunately,  a 
recent decision of the Cour de cassation
108
 suggests that it has performed yet another 
reversal in upholding the Court of Appeal of Versaille’s decision109 that temporal 
proximity between the hepatitis B vaccination and the appearance of the 
demyelinating disease, in the absence of any other known cause for the disease, 
allowed a presumption that the vaccine had caused the claimant’s injury. However, it 
also ruled, in overturning the decision of the Court of Appeal, that it should have 
checked if the elements, on the basis of which causation had been presumed, did not 
also allow a presumption that the vaccine was defective. It therefore suggests that the 
elements that allow for a presumption of causation may also allow for a presumption 
of defectiveness. Professor Borghetti has noted that this form of ‘intuitive’ reasoning 
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is unsupported by scientific evidence,
110
 and as Fairgrieve and G’Sell-Macrez 
observe, the ‘constant reference to “serious precise and concurrent presumptions” 
seems somehow to prevent French courts from adopting probabilistic reasoning 
regarding causation’.111 It seems that lower French law courts are free to follow their 
own approaches to the potential link between hepatitis B vaccinations and 
demyelinating diseases. While a majority of lower courts, including the Paris Court of 
Appeal, consider that the current state of scientific uncertainty does not permit 
causation to be presumed on the facts of the case, irrespective of the temporal 
proximity between the hepatitis B vaccination and the appearance of the 
demyelinating disease, in a minority of cases the appellate courts are prepared to 
recognise such a presumption. Unfortunately, this   recent decision of the Cour de 
cassation follows that minority view. However, in its most recent decision, the Cour 
de cassation, while upholding the approach of assessing all elements at hand when 
considering a product’s defectiveness and the existence of a causal link, has now also 
held that demonstration of ‘imputability’(i.e. general causation between a product and 
a disease) must be met as a prerequisite prior to the demonstration of damage, defect 
and causal link.
112
 It appears that the aim of this approach is to prevent a complete 
disconnection between causation in science and law, but it will also result in an 
increase in the claimant’s burden of proof.113The inconsistency of these decisions has 
been unhelpful in generating uncertainty for both claimant and defendant. However, it 
is submitted that, without scientific evidence of general causation, there should be no 
question of overcoming the burden of proof of causation in such cases. The Cour de 
cassation would be wise to study the factors required to overcome that burden as 
established in the National Vaccine Injury Compensation Program.
114
 While the 
current decisions of the French courts appear to accept prongs two and three of the 
Althen
115
 test, viz (2) a logical sequence of cause and effect showing that the 
vaccination was the reason for the injury; and (3) a showing of a proximate temporal 
relationship between the vaccination and the injury, the uncertainty seems to stem 
from whether there should be an acceptance of prong (1), ie a medical theory causally 
connecting the vaccination and the injury, which is a general causation requirement 
that the type of vaccine can cause the type of injury in question.
116
  
Were the French courts to adopt an Althen type approach, which gives 
primacy to the general causation issue, this would help create more consistency in its 
decisions, in line with the Cour de cassation’s objective laid down in its Annual 
Report for 2008 to harmonise case law on the hepatitis B vaccine.
117
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VI. MMR AND THE GENERAL MEDICAL COUNCIL 
A. The Professional Conduct Hearing 
While the test cases have come to their conclusion, the position in the UK shifted to 
issues of professional misconduct on behalf of Dr Wakefield, and two other doctors 
who were co-authors on the Lancet paper, viz Professor Walker-Smith and Professor 
(formerly Dr) Murch. These three doctors were referred to the General Medical 
Council, the body in the UK which is charged with the role of protecting, promoting 
and maintaining the health and safety of the public by ensuring proper standards in the 
practice of medicine.
118
 
 After a hearing lasting 148 days which took over two and a half years to 
complete, the longest in the history of the GMC, Wakefield was found guilty of 
dishonesty and irresponsibility by the GMC. In particular, they found that: he had 
carried out research on the children in breach of Research and Ethics Committee 
approval;
119
 he had subjected several children to intrusive procedures such as lumber-
puncture and colonoscopy that were not clinically indicated;
120
 he had intentionally 
misled the Legal Aid Board by failing to disclose that certain funding subsequently 
provided by them was not required; he had caused or permitted public funds supplied 
by the Legal Aid Board to be used for purposes other than those for which it was 
needed; in respect of conflict of interests, he had failed to disclose to the Editor of the 
Lancet his involvement in the MMR Litigation and that the study had received 
funding from the Legal Aid Board; and that he had filed a patent application for a new 
vaccine for the elimination of the MMR and measles virus and for the treatment of 
inflammatory bowel disease.
121
 He also unethically caused blood to be taken from a 
group of children for research purposes at his son’s birthday party.122 In all these 
circumstances, and taking into account the standard that might be expected of a doctor 
practising in the same field of medicine in similar circumstances, the Panel concluded 
that Wakefield’s misconduct not only collectively amounted to serious professional 
misconduct, but also, when considered individually, constituted multiple separate 
instances of serious professional misconduct.
123
 The Panel concluded that Dr 
Wakefield’s shortcomings and the aggravating factors in this case124 could not be 
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addressed by any condition on his registration. Accordingly, it determined that his 
name should be erased from the medical register, concluding that this was 
the only sanction that [was] appropriate to protect patients and [was] in the wider 
public interest, including the maintenance of public trust and confidence in the 
profession and [was] proportionate to the serious and wide-ranging findings made 
against him.
125
 
The Panel also concluded that the only appropriate sanction against Professor Walker-
Smith was erasure from the medical register.
126
 However, while the Panel concluded 
that Professor Murch had demonstrated errors of judgement, he had acted in good 
faith, and any professional misconduct on his part could not reach the threshold of 
serious professional misconduct.
127
 
B. Consequences of the Professional Conduct Hearing 
On 6 February 2010, about a week after the findings of fact made against Wakefield 
and his colleagues, and 12 years after its original publication, the Editors of the 
Lancet finally retracted the 1998 Lancet paper. It has been submitted that this should 
not have taken so long and that until the article’s retraction, both Wakefield and 
claimants could continue to argue that their position was supported in a peer-reviewed 
journal, albeit an article which had not received general acceptance. Part of the 
problem here – as any respected epidemiologist will tell us – is that no study can 
entirely rule out the possibility of a link between MMR and autism. But under the 
burden of proof in law, it was the claimants who were required to show such a link; 
there was no burden on the defendants to shown that there was none. It is clear that 
they decisively failed in the United States, and that there was no prospect of them 
succeeding in the UK.  
By the time of its retraction few could deny that Wakefield’s Lancet paper was 
fatally flawed, both scientifically and ethically.
128
 However, to compound matters, 
even more disturbing news was to emerge. In early 2011, a series of articles in the 
British Medical Journal claimed that the 1998 Lancet paper was fraudulent on the 
basis that in not one of the 12 cases could the medical records be fully reconciled with 
what was published in the descriptions, diagnoses or histories in the journal.
129
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VII. CONCLUSION 
The MMR litigation has shown the incalculable damage that can be caused by one 
peer reviewed article in a prestigious scientific journal. But for this article, the 
ensuing publicity in the UK and US would never have transpired. It was this article 
which fuelled the publicity, which in turn generated the law suits on both sides of the 
Atlantic. More importantly, it can be argued, it resulted in considerable damage to 
public health. While vaccination rates in the UK have recovered slightly, they remain 
below the 95 per cent level recommended by the World Health Organisation to ensure 
herd immunity.
130
 The other damage in the UK was that since the MMR Litigation, 
the Legal Services Commission became reluctant to fund other multi-party actions in 
respect of medicinal products that claimants alleged had caused harm.
131
  
While there was considerable justification for withdrawal of public funding in 
the UK, there are some positives that have emerged from the test cases in the US 
Omnibus Autism Proceeding. Indeed, it is arguable that the US experience in the test 
cases in autism is in many ways a paradigm of how to address such controversial 
issues. Unburdened by the emotions of a jury and the usual restrictions imposed by 
the Federal Rules of Evidence, a single trier of fact has been able to look at all the 
available evidence and come to a reasoned decision. In these autism test cases, issues 
of general and specific causation have been addressed and factors personal to the 
individual children have been taken into account. While the Daubert factors have 
been utilised, they have not prevented evidence being made admissible in these 
proceedings through an overly strenuous evidentiary threshold. They have been 
relevant to the assessment of weight at the adjudication stage, which has allowed the 
evidence as a whole to ventilate in the proceedings. It suggests that this more flexible 
approach to scientific evidence, albeit with high standards at the adjudication stage, is 
welcome and may counter some of the criticisms
132
 of Daubert that it has in some 
cases hindered the search for justice in product liability law. No doubt the most 
radical approach would be to build on the template of the National Vaccine Injury 
Compensation Program, and extend it to one involving all prescription drugs 
generally. This is unlikely to take place in the short term. But what should be possible 
is a greater flexibility in the use the gatekeeping role for scientific evidence in these 
types of cases.  
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In France, a liberal approach to causation appeared to be established in France 
by the Cour de cassation, principally in the context of claims for compensation for 
demyelinating diseases, allegedly caused or exacerbated by vaccinations against 
hepatitis B. The Cour de cassation has acknowledged that causal link can be 
established by the presence of serious, precise and concurrent presumptions of 
causation. However, the inconsistency of the decisions has been unhelpful in 
generating uncertainty for both claimant and defendant. It is submitted that, without 
scientific evidence of general causation, there should be no question of overcoming 
the burden of proof of causation in such cases. The Cour de cassation would be wise 
to study the factors required to overcome that burden as established in the National 
Vaccine Injury Compensation Program, as adumbrated in the Althen case, and utilised 
by the OAP test cases, which, it is submitted, generate more clarity and consistency in 
approach.  
There are also lessons to be learned from the outcome of the General Medical 
Council hearing. In particular, co-authors of scientific papers will require to verify the 
source data of studies in a more thorough manner than they have done previously.
133
 
Such researchers will need to remember that they have a duty to disclose not only 
actual conflicts of interest, but also perceived conflicts.
134
 Research Ethics 
Committees will be required to establish mechanisms to determine that what was done 
in a study was actually permitted; they must also be required to work to an effective 
governance procedure that can impose sanctions when an eventual publication proves 
that unpermitted acts have taken place.
135
  
 Another important lesson lies with the role of the media in its reporting of the 
MMR vaccine scare. They repeatedly reported the concerns of Wakefield, without 
giving methodological details of the research, whilst ignoring the epidemiological 
evidence showing no link between MMR and autism.
136
 It is important that in future 
the media recognise the importance of peer-reviewed scientific evidence in such 
cases, and report it impartially. 
However, the principal lesson to be learned from the MMR litigation lies with 
the wider scientific community. In exercising its freedom to sanction, conduct and 
publish scientific research, the scientific community as a whole must always exercise 
eternal vigilance against scientific fraud and misconduct. It is only in these 
circumstances that good science will have the necessary confidence of the public and 
the legal system that engages with it.   
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